GlaxoSmithKline Receivables Trend from 2010 to 2021

GSK -  USA Stock  

USD 39.84  0.73  1.80%

GlaxoSmithKline PLC Trade and Non Trade Receivables is increasing with slightly volatile movements from year to year. Trade and Non Trade Receivables is estimated to finish at about 7.1 B this year. For the period between 2010 and 2021, GlaxoSmithKline PLC, Trade and Non Trade Receivables quarterly trend regression had mean deviation of 617,350,877 and r-value of  0.79. GlaxoSmithKline PLC Revenues is increasing as compared to previous years. The last year's value of Revenues was reported at 34.1 Billion. The current Selling General and Administrative Expense is estimated to increase to about 11.7 B, while Cost of Revenue is projected to decrease to under 11.5 B.

Search Historical Trends 

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline main balance sheet or income statement drivers, such as Direct Expenses of 10 B, Consolidated Income of 5.9 B or Cost of Revenue of 11.5 B, as well as many exotic indicators such as Interest Coverage of 7.51, Long Term Debt to Equity of 2.32 or Calculated Tax Rate of 8.59. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules. It can also supplement various GlaxoSmithKline PLC Technical models. Please check the analysis of GlaxoSmithKline PLC Correlation against competitors.

GlaxoSmithKline Receivables Breakdown

Showing smoothed Receivables of GlaxoSmithKline PLC with missing and latest data points interpolated. GlaxoSmithKline PLC's Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.
Receivables10 Years Trend
Slightly volatile

GlaxoSmithKline Receivables Regression Statistics

Arithmetic Mean 5,710,619,219
Geometric Mean 5,675,631,625
Coefficient Of Variation 11.41
Mean Deviation 446,389,088
Median 5,692,000,000
Standard Deviation 651,475,574
Range 2,538,000,000
R-Value 0.57
R-Squared 0.32
Significance 0.06
Slope 102,124,954

GlaxoSmithKline Receivables History

20115.6 B
20125.2 B
20135.4 B
20144.3 B
20155.3 B
20165.7 B
20175.7 B
20186.1 B
20196.9 B
20206.6 B
20215.9 B

Other Fundumenentals of GlaxoSmithKline PLC

GlaxoSmithKline PLC Receivables component correlations

About GlaxoSmithKline PLC Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's Receivables, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Receivables6.6 B5.9 B
Trade and Non Trade ReceivablesB7.1 B
Receivables Turnover 5.05  4.75 
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on New York Stock Exchange. It employs 94066 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in GlaxoSmithKline PLC without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Shere Portfolio Now


Shere Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as GlaxoSmithKline PLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of GlaxoSmithKline PLC Correlation against competitors. Note that the GlaxoSmithKline PLC information on this page should be used as a complementary analysis to other GlaxoSmithKline PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for GlaxoSmithKline PLC Stock analysis

When running GlaxoSmithKline PLC price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
The market value of GlaxoSmithKline PLC is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine GlaxoSmithKline PLC value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.